Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Phase 3
Terminated
- Conditions
- Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Interventions
- Drug: Standard of Care ChemotherapyDrug: Blinatumomab
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 405
- Registration Number
- NCT02013167
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 310
- Registration Number
- NCT02010931
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Other: Not applicable - observational study
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2373
- Registration Number
- NCT02003612
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Phase 2
Completed
- Conditions
- Relapsed/Refractory Philadelphia Positive B-precursor ALL
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT02000427
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
Phase 2
Completed
- Conditions
- Postmenopausal Osteoporosis (PMO)
- Interventions
- Drug: PlaceboDrug: Romosozumab
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 252
- Registration Number
- NCT01992159
- Locations
- 🇯🇵
Research Site, Toshima-ku, Tokyo, Japan
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
Phase 3
Completed
- Conditions
- Hyperlipidemia
- Interventions
- Drug: EzetimibeOther: Placebo to EzetimibeDrug: EvolocumabDrug: AtorvastatinDrug: Placebo to AtorvastatinOther: Placebo to Evolocumab
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 511
- Registration Number
- NCT01984424
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid
Completed
- Conditions
- Osteonecrosis of the JawInfection Leading to Hospitalization
- First Posted Date
- 2013-10-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2560
- Registration Number
- NCT01967160
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 158
- Registration Number
- NCT01932970
- Locations
- 🇺🇸
Research Site, Hampton, Virginia, United States
Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
Phase 4
Terminated
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- Interventions
- Biological: EtanerceptDrug: Methotrexate
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 90
- Registration Number
- NCT01927757
- Locations
- 🇵🇷
Research Site, Caguas, Puerto Rico
A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: AMG 282Drug: AMG 282 Matching Placebo
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2016-12-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 70
- Registration Number
- NCT01928368
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath